Skip to main content

Table 3 Predicted upstream regulators affected in GOT1 tumors after 177Lu-octreotate therapy with priming

From: Transcriptional effects of 177Lu-octreotate therapy using a priming treatment schedule on GOT1 tumor in nude mice

 

Upstream regulator

z

p

Targets from transcriptional data

1 day

 

GDF15

6.1 × 10−6

↑CDKN1A, ↑GDF15

 

PPP5C

1.8 × 10−5

↑CDKN1A, ↑SGK

 

SATB1

0.11

7.8 × 10−5

↑CDKN1A, ↑F5, ↑FAM129A, ↑SGK

 

RNF2

1.3 × 10−4

↑CDKN1A, ↑GDF15

 

FH

2.2 × 10−4

↑APOD, ↑CDKN1A

3 days

p53

3.3

6.0 × 10−14

↑ACTA2, ↑APOE, ↑BAX, ↑CCND3, ↑CDKN1A, ↓CTGF, ↑DDB2, ↑DDIT3, ↓FDFT1, ↑GADD45A, ↑GDF15, ↑NINJ1, ↓PBK, ↑PHLDA3, ↑SPATA18, ↑TIGAR, ↑TNFRSF10B, ↑VCAN

ANXA2

−2.0

8.1 × 10−9

↑BAX, ↑CDKN1A, ↑GADD45A, ↑TNFRSF10B, ↑ZMAT3

 

MYC

−0.32

2.0 × 10−8

↑BAX, ↑CCND3, ↑CDKN1A, ↑DDB2, ↑DDIT3, ↓EXOSC8, ↑GADD45A, ↑HSPH1, ↑TNFRSF10B

 

PPARGC1A

0.32

8.3 × 10−8

↑BAX, ↑CDKN1A, ↓INSIG1, ↓LDLR, ↑TIGAR

KDM5B

2.6

2.0 × 10−5

↑DDIT3, ↓DLGAP5, ↑GADD45A, ↓INSIG1, ↓PBK

7 days

 

PPARG

0.17

9.8 × 10−8

↑ACTA2, ↑CDH1, ↑CDKN1A, ↑CTSL, ↓INSIG1, ↓PDK4

PARP1

−2.0

3.7 × 10−7

↑CDH1, ↓PEG10, ↓TMSB15A, ↑TNFRSF10B

 

p53

1.9

1.0 × 10−6

↑ACTA2, ↑APOE, ↑CDH1, ↑CDKN1A, ↑F5, ↓FDFT1, ↑GDF15, ↑NINJ1, ↓PEG10, ↑PHLDA3, ↓TMSB15A, ↑TNFRSF10B

 

SKI

1.1 × 10−6

↑ACTA2, ↑CDH1, ↑CDKN1A

 

GDF15

1.5 × 10−5

↑CDKN1A, ↑GDF15

41 days

LIN28B

4.5 × 10−5

↓BCL11A, ↓SOX2

 

ID1

1.9 × 10−4

↓EGR1, ↓SOX2

CDX2

1.1 × 10−3

↓NR2F2, ↓SOX2

 

SHP

1.3 × 10−3

↓EGR1

 

mir-140

1.3 × 10−3

↓SOX2

  1. Significantly affected upstream regulators identified with IPA (Fisher’s exact test, p < 0.05), ranked according to the lowest p value, for each time point. z scores indicate activation state of the upstream regulator; z > 2 indicates activation, and z < −2 indicates inhibition. Up and down arrows indicate upregulated and downregulated genes in tumor samples from treated animals compared with controls, respectively. indicates the upstream regulator was not affected in animals treated with 15 MBq single administration of 177Lu-octreotate (from GEO accession GSE80024)